IDiyas

For the Inventor, By the Inventor

Cincinnati, OH, United States of America

Biswanath De

USPTO Granted Patents = 59

Average Co-Inventor Count = 5.4

ph-index = 15

Forward Citations = 603(Granted Patents)


Inventors with similar research interests:


Location History:

  • Vernon Hills, IL (US) (1990 - 1993)
  • Buffalo Grove, IL (US) (1993)
  • Mason, OH (US) (1999)
  • Cincinatti, OH (US) (2001)
  • Cincinnati, OH (US) (1994 - 2008)

Company Filing History:

goldMedal46 out of 17,164 
 
The Procter Gamble Company
 patents
silverMedal10 out of 4,177 
 
Abbott Laboratories Corporation
 patents
bronzeMedal2 out of 308 
 
The Proctor 'gamble Company
 patents
4. 1 out of 832,680 
Other
 patents

Years Active: 1990-2008

Loading Chart...
59 patents (USPTO):Explore Patents
1. 7449474 - Tri-substituted ureas as cytokine inhibitors (2008-11-11),
2. 7402589 - Tri-substituted ureas as cytokine inhibitors (2008-07-22),
3. 7319102 - Pyrrolo[2,3-d]pyrimidine cytokine inhibitors (2008-01-15),
4. 7256196 - Purine cytokine inhibitors (2007-08-14),
5. 7138395 - Interleukin-1β converting enzyme inhibitors (2006-11-21),
6. 7087615 - 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which provide analgesia (2006-08-08),
7. 7041696 - Interleukin-1β converting enzyme inhibitors (2006-05-09),
8. 7001899 - Interleukin converting enzyme inhibitors (2006-02-21),
9. 6949545 - Heterocyclic side chain containing, n-substituted metalloprotease inhibitors (2005-09-27),
10. 6919346 - Isoxazolone compounds useful in treating diseases associated with unwanted cytokine activity (2005-07-19),
11. 6872742 - Substituted cyclic amine metalloprotease inhibitors (2005-03-29),
12. 6858628 - Substituted cyclic amine metalloprotease inhibitors (2005-02-22),
13. 6852751 - Difluorobutyric acid metalloprotease inhibitors (2005-02-08),
14. 6821971 - Fused pyrazolone compounds which inhibit the release of inflammatory cytokines (2004-11-23),
15. 6790846 - Isoxazolone compounds useful in treating diseases associated with unwanted cytokine activity (2004-09-14),

Title: Innovator Spotlight: Biswanath De - Pioneering Cytokine Inhibitor Technologies

Introduction: Meet Biswanath De, a prolific inventor based in Cincinnati, OH, with an impressive portfolio of 59 patents. His groundbreaking work in developing cytokine inhibitors is revolutionizing the treatment of inflammatory diseases.

Latest Patents: Biswanath De's latest patents showcase his expertise in cytokine inhibition. The invention of 1,1,3-tri-substituted ureas as cytokine inhibitors represents a significant breakthrough in targeting inflammatory cytokines linked to various disease states in humans and higher mammals.

Career Highlights: Biswanath De has made significant contributions to companies like The Procter & Gamble Company and Abbott Laboratories Corporation. His innovative research and patented technologies have led to advancements in the field of biochemistry and pharmaceuticals.

Collaborations: Throughout his career, Biswanath De has collaborated with esteemed professionals in the industry, including Michael G Natchus and Neil Gregory Almstead. These partnerships have played a crucial role in the development and commercialization of his groundbreaking inventions.

Conclusion: Biswanath De's dedication to innovation and his pioneering work in cytokine inhibition have earned him a reputation as a leading figure in the field of biochemistry. His patents not only demonstrate his technical expertise but also highlight his commitment to improving healthcare outcomes for patients worldwide.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…